See the DrugPatentWatch profile for azacitidine

Azacitidine is a medication commonly used to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). While it has been shown to be effective in treating these conditions, it is essential to understand its potential effects on normal platelet count.

Studies have demonstrated that azacitidine can influence normal platelet count. A study published in the Journal of Clinical Oncology found that azacitidine treatment led to a significant decrease in platelet counts in patients with MDS and AML [1]. Another study published in the British Journal of Haematology found that azacitidine therapy was associated with a decline in platelet counts in patients with MDS [2].

However, it is essential to note that the impact of azacitidine on normal platelet count can vary depending on the individual patient and their specific condition. A study published in the Journal of Clinical Oncology found that azacitidine treatment led to a significant decrease in platelet counts in patients with MDS and AML [1]. In contrast, a study published in the British Journal of Haematology found that azacitidine therapy was associated with a decline in platelet counts in patients with MDS [2].

In conclusion, azacitidine can influence normal platelet count, and its impact can vary depending on the individual patient and their specific condition. It is essential for patients receiving azacitidine therapy to closely monitor their platelet counts and work closely with their healthcare provider to manage any potential side effects.

Sources:

[1] Journal of Clinical Oncology. (2011). Azacitidine for the treatment of myelodysplastic syndromes. Retrieved from <https://ascopubs.org/doi/10.1200/JCO.2010.31.4441>

[2] British Journal of Haematology. (2015). Azacitidine for the treatment of myelodysplastic syndromes. Retrieved from <https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13441>

[3] DrugPatentWatch.com. (n.d.). Azacitidine Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent-expiration-dates/azacitidine>

Note: The sources cited are a selection of the available information and are not exhaustive.